OHSU

IRB #

IRB00006867

Title

A Phase 1 Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients with Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy with TemodarĀ® in Patients with Glioblastom Multiforme

Principal Investigator

Matthew Taylor

Study Purpose

The purpose of this study is to determine the safety and tolerability of the study drug (CTO) when given to patients with advanced or metastatic solid tumors.

Medical Condition(s)

Multiple disease sites

Eligibility Criteria

*Subjects should have advanced or metastatic solid tumors for which there is no standard therapy;
*Subjects must have received prior anticancer therapy or not be eligible for any established convential therapy;
*Subjects must be men or women 18 years or older;
* Subjects may not have had prior treatment 4 week prior to study entry.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Tactical Therapeutics, Inc./INDUSTRY

Recruitment End

Compensation Provided

No


Go Back